Jane bell joins mesoblast board

New york, aug. 18, 2022 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed jane bell to its board of directors. ms bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the united states, canada, australia and the united kingdom, including funds management, mergers, acquisitions, and divestments. she has served as a non-executive director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management.
MESO Ratings Summary
MESO Quant Ranking